Eli Lilly and

Yahoo Finance • 3 hours ago

Sector Update: Health Care Stocks Higher Late Afternoon

Health care stocks rose late Tuesday afternoon, with the NYSE Health Care Index up 0.4% and the Stat PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 6 hours ago

Eli Lilly Broadens Oncology Portfolio As Investors Reassess Valuation Potential

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Eli Lilly (NYSE:LLY) agreed to acquire CrossBridge Bio, a pre clinical ADC company focused on dual payload TROP2 therapies,... Full story

Yahoo Finance • 7 hours ago

Novo Bets on OpenAI to Rebuild Its Obesity Edge

This article first appeared on GuruFocus. Novo Nordisk (NYSE:NVO) rose 3.46% on the Copenhagen exchange after partnering with OpenAI to deploy AI across drug discovery, manufacturing, andcommercial operations, as it looks to regain moment... Full story

Yahoo Finance • 7 hours ago

Jim Cramer on Johnson & Johnson: “If It Gets Blasted, Try to Get Some”

Johnson & Johnson (NYSE:JNJ) is among the stocks on Jim Cramer’s game plan as he shared his take on the market post Iran-U.S. ceasefire talks. Cramer noted that it has become his favorite drug stock instead of Eli Lilly, as he said: Now,... Full story

Yahoo Finance • 8 hours ago

Dyslexia Treatment Market Report 2026: $40+ Bn Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F

Dublin, April 14, 2026 (GLOBE NEWSWIRE) -- The "Dyslexia Treatment Market Report 2026" has been added to ResearchAndMarkets.com's offering. The dyslexia treatment market is poised for significant growth, expanding from $30.17 billion i... Full story

Yahoo Finance • 8 hours ago

REX LLY Growth & Income ETF 3Shs announces weekly distribution of $0.1351

* REX LLY Growth & Income ETF 3Shs (LLII [https://seekingalpha.com/symbol/LLII]) announces weekly distribution of $0.1351, -23.84% lower from the prior week's distribution of $0.1774. * The annual distribution rate is 32.01%, with an S... Full story

Yahoo Finance • 8 hours ago

Novo Nordisk Stock Rises. How OpenAI Can Help It Find the Next Ozempic.

Novo Nordisk stock was rising on Tuesday after the Ozempic and Wegovy maker unveiled a partnership with ChatGPT developer OpenAI that it said would speed up drug discovery. Novo’s American depositary receipts climbed 2.8% to $39.03 in earl... Full story

Yahoo Finance • 10 hours ago

Linden Lake Labs Applauds Acquisition of Portfolio Company CrossBridge Bio by Eli Lilly and Company

Transaction validates dual-payload ADC platform and reinforces Linden Lake Labs’ life sciences platform for advancing breakthrough therapies ROCKVILLE, Md., April 14, 2026--(BUSINESS WIRE)--Linden Lake Labs ("L3"), an early-stage life sci... Full story

Yahoo Finance • 10 hours ago

Novo Nordisk Taps OpenAI to Accelerate Drug Development

This article first appeared on GuruFocus. Novo Nordisk A/S (NVO, Financials) is working with OpenAI to use artificial intelligence more in its business, from early-stage drug development to making drugs and running the business every day.... Full story

Yahoo Finance • 11 hours ago

Vasa Therapeutics Partners with Lilly TuneLab to Power AI/ML-Driven CAMKII Inhibitor Platform

Vasa's CAMKII delta inhibitor, a leading discovery and development platform built on extensive crystallography data, will utilize Lilly TuneLab AI/ML predictive models to accelerate candidate selection. First-in-Human study planned for 202... Full story

Yahoo Finance • 11 hours ago

CrossBridge Bio Enters an Agreement to be Acquired by Eli Lilly to Advance Next-Generation Dual-Payload Antibody-Drug Conjugates

CrossBridge Bio’s pipeline includes a potential best-in-class TROP2-targeting TOP1i/ATRi dual-payload ADC anticipated to enter the clinic in 2026 Acquisition provides an innovative synergistic dual payload platform for the development of... Full story

Yahoo Finance • 16 hours ago

Wegovy-maker Novo Nordisk partners with OpenAI to speed drug development

By Maggie Fick LONDON, April 14 (Reuters) - Danish drugmaker Novo Nordisk, which has fallen behind Eli Lilly in the immensely lucrative weight-loss drug market, said on Tuesday it ‌is partnering with OpenAI to deploy artificial intelligen... Full story

Yahoo Finance • yesterday

1 Profitable Stock to Own for Decades and 2 That Underwhelm

Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential. Profits are valuable, but they’re not ev... Full story

Yahoo Finance • yesterday

Eli Lilly Advances Leukemia Drug in Late-Stage Trial

This article first appeared on GuruFocus. Eli Lilly and Company (LLY, Financials) announced that its leukemia drug Jaypirca did well in a Phase 3 clinical trial. This is a good thing for the company's cancer pipeline.The major goal of the... Full story

Yahoo Finance • yesterday

After Obtaining Approval for Its Weight Loss Pill, Is It Off to the Races for Eli Lilly Stock?

On April 1, Eli Lilly(NYSE: LLY) and its shareholders received the news they were eagerly awaiting: the approval of the company's GLP-1 pill, Foundayo. While the company isn't the first out of the gate with a GLP-1 pill, it's still a massi... Full story

Yahoo Finance • yesterday

Leal Therapeutics Announces Executive Leadership Appointments and Provides Business Update

WORCESTER, Mass., April 13, 2026 /PRNewswire/ -- Leal Therapeutics, Inc. (Leal), a biotechnology company developing neuro-metabolic therapeutics, today announced the appointments of Johannes Tauscher, M.D., as Chief Medical Officer and Ray... Full story

Yahoo Finance • yesterday

Lyumjev (Eli Lilly and Co) Market Research Report 2026: Epidemiology, Pipeline Analysis, Insights & Forecasts, 2020-2025, 2025-2030F, 2035F

Company Logo Key market opportunities for Lyumjev include increased diabetes prevalence, demand for rapid and personalized insulin therapies, integration with digital glucose management, and home-based care expansion. Rising health expend... Full story

Yahoo Finance • yesterday

Lilly's Jaypirca (pirtobrutinib) significantly extended progression-free survival when added to a venetoclax time-limited regimen in patients with previously treated CLL/SLL

BRUIN CLL-322 is the first Phase 3 readout in CLL to utilize and outperform a venetoclax-containing control arm This trial predominantly enrolled a patient population previously treated with covalent BTK inhibitors, highly relevant to cur... Full story

Yahoo Finance • 2 days ago

ER+/ HER2 - ve Breast Cancer Market Insight, Epidemiology, and Market Forecast Report 2022-2036

Company Logo Opportunities in the ER+/HER2- breast cancer market include the growth of novel CDK4/6 inhibitors and next-generation SERDs, offering advanced treatment options. Strong R&D from players like AstraZeneca and Roche, coupled wit... Full story

Yahoo Finance • 2 days ago

The Post-Ozempic Economy? 2 Industries Bracing for a Slimmer, Less Hungry America

Investors are hyper-focused on what artificial intelligence (AI) will do to the economy. But what if the bigger disruptors -- at least for consumers -- are the revolutionary weight-loss drugs? Revenue for these GLP-1 drugs is actually high... Full story